NM
HUMA icon

Newtyn Management’s Humacyte HUMA Stock Holding History

Newtyn Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-40,333
Closed -$437K – 94
2021
Q1 		$437K Buy
+40,333
New +$440K 0.12% 72

Other funds holding HUMA

MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
PSAMP
P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
ACA
Arena Capital Advisors Los Angeles, California $200M AUM 23.6% 1-Year Est. Return

Newtyn Management's HUMA Position: Q2 2021 in Review

Newtyn Management sold out of Humacyte (HUMA) in Q2 2021, closing a stake of 40,333 shares — an estimated $437K sold.

Newtyn Management first reported a position in HUMA in Q1 2021 and held it in 1 quarter. The position peaked at $437K in Q1 2021. 28 funds tracked by Wall St. Rank hold HUMA as of Q2 2021.

  • Newtyn Management reported no remaining Humacyte position as of Q2 2021 after selling out during the quarter.
  • Newtyn Management sold 40,333 Humacyte shares in Q2 2021, an estimated $437K.
  • Newtyn Management first reported a position in Humacyte in Q1 2021 and held it in 1 quarter.
  • Newtyn Management's Humacyte position peaked at $437K in Q1 2021.
  • 28 funds tracked by Wall St. Rank held Humacyte as of Q2 2021.

Based on Newtyn Management's 13F filing for Q2 2021, filed 16 Aug 2021.